Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity (Q41342184)

29 September 2017

1 reference

title

Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity (English)

1 reference

29 September 2017

0 references

1

Rooney CM

1 reference

29 September 2017

3

Heslop HE

1 reference

29 September 2017

Smith CA

2

1 reference

29 September 2017

1 January 1997

1 reference

Trends in Molecular Medicine

29 September 2017

1 reference

29 September 2017

3

1 reference

29 September 2017

1

1 reference

29 September 2017

24-30

1 reference

NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management

29 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Epstein-Barr virus strategy in normal and neoplastic B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

CpG methylation of viral DNA in EBV-associated tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Epstein-Barr Virus DNA recombination and loss in sporadic Burkitt's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Donor T cells to treat EBV-associated lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910054-X

7 January 2021

10.1016/S1357-4310(96)10054-X

Identifiers

DOI

1 reference

29 September 2017

1 reference

PubMed ID

9021739